These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844 [TBL] [Abstract][Full Text] [Related]
5. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061 [TBL] [Abstract][Full Text] [Related]
6. [MGMT and temozolomide sensibility]. Tabouret E Bull Cancer; 2021 Dec; 108(12):1075-1076. PubMed ID: 34782119 [No Abstract] [Full Text] [Related]
7. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
8. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study. Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781 [TBL] [Abstract][Full Text] [Related]
9. High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas. Saito T; Sugiyama K; Hama S; Yamasaki F; Takayasu T; Nosaka R; Onishi S; Muragaki Y; Kawamata T; Kurisu K World Neurosurg; 2017 Sep; 105():282-288. PubMed ID: 28602885 [TBL] [Abstract][Full Text] [Related]
10. One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned? Heiland DH; Haaker G; Watzlawick R; Delev D; Masalha W; Franco P; Machein M; Staszewski O; Oelhke O; Nicolay NH; Schnell O J Neurooncol; 2018 Nov; 140(2):385-391. PubMed ID: 30076585 [TBL] [Abstract][Full Text] [Related]
11. Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. Fabi A; Russillo M; Metro G; Vidiri A; Di Giovanni S; Cognetti F Anticancer Res; 2009 Jul; 29(7):2607-10. PubMed ID: 19596935 [TBL] [Abstract][Full Text] [Related]
12. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Li H; Li J; Cheng G; Zhang J; Li X Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705 [TBL] [Abstract][Full Text] [Related]
13. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131 [TBL] [Abstract][Full Text] [Related]
15. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics. St-Coeur PD; Poitras JJ; Cuperlovic-Culf M; Touaibia M; Morin P J Neurooncol; 2015 Oct; 125(1):91-102. PubMed ID: 26311249 [TBL] [Abstract][Full Text] [Related]
16. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. Franceschi E; Depenni R; Paccapelo A; Ermani M; Faedi M; Sturiale C; Michiara M; Servadei F; Pavesi G; Urbini B; Pisanello A; Crisi G; Cavallo MA; Dazzi C; Biasini C; Bertolini F; Mucciarini C; Pasini G; Baruzzi A; Brandes AA; J Neurooncol; 2016 May; 128(1):157-162. PubMed ID: 26943851 [TBL] [Abstract][Full Text] [Related]
17. Association between response to primary treatments and MGMT status in glioblastoma. Franceschi E; Tosoni A; Pozzati E; Brandes AA Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238 [TBL] [Abstract][Full Text] [Related]
18. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ; Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895 [TBL] [Abstract][Full Text] [Related]
19. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046 [TBL] [Abstract][Full Text] [Related]
20. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Wiewrodt D; Nagel G; Dreimüller N; Hundsberger T; Perneczky A; Kaina B Int J Cancer; 2008 Mar; 122(6):1391-9. PubMed ID: 18000822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]